Form: 8-K

Current report filing

November 14, 2022

Exhibit 99.1


 Aethlon Medical Logo


Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update


SAN DIEGO, Nov. 14, 2022 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.


Company Updates


Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood. This action has potential applications in cancer, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases, including removal of COVID-19 virus, associated variants, and related exosomes.


· Due to a scarcity of COVID patients in intensive care units eligible for enrollment into our U.S. COVID trial, we recently decided to terminate the agreement with our contract research organization (CRO). As a result, while our Investigational Device Exemption (IDE) related to severe viral infections remains open, we are discontinuing U.S. COVID clinical trial activity. We expect this decision to save the company up to $5 million over the next twelve months, which we intend to allocate towards advancing the study of our Hemopurifier in oncology.


· Due to lack of patient enrollment by the University of Pittsburgh Medical Center (UPMC) in our head and neck cancer safety trial, we and UPMC have terminated this study. We are planning a new clinical trial in oncology that will potentially include more tumor types, enabling us to build our safety database in oncology and provide data to help direct the development of our Hemopurifier as a treatment option in oncology. We are in the latter stages of selecting a new CRO to supervise this new oncology study.


· In October 2022, we launched a wholly owned subsidiary in Australia, formed to conduct clinical research, seek regulatory approval, and commercialize our Hemopurifier in that country. The subsidiary will initially focus on the oncology market in Australia. Once selected, it is likely that our new CRO will oversee planned oncology studies in both the U.S. and Australia.


· Our COVID-19 trial site in India remains open with the goal of enrolling additional COVID-19 patients. We are considering opening an oncology trial in India as well.


· The addition of a second supplier for Galanthus nivalis agglutinin (GNA), used in the resin of our Hemopurifier, is delayed in the U.S., pending approval by the U.S. Food and Drug Administration (FDA) of the supplement to our IDE required to enact this manufacturing change. In our opinion, the FDA has mandated unexpectedly high testing requirements for a product in the safety and feasibility stage of development. The additional data requested by FDA may take us several months to obtain. We are escalating our concerns with the FDA decision by engaging the FDA’s ombudsman. However, there can be no assurance that this escalation will accelerate our development timelines.


· Regulatory authorities in India have accepted this manufacturing change and, as a result, we will ship new cartridges to the site in India for use in our clinical trials there.


· We have engaged a major testing lab, Battelle (Columbus, OH), to perform an in vitro study to examine the binding of the current Monkeypox strain to a miniature version of our Hemopurifier.







Financial Results for the Second Quarter Ended September 30, 2022


As of September 30, 2022, Aethlon Medical had a cash balance of approximately $19.6 million.


Consolidated operating expenses for the three months ended September 30, 2022 were approximately $3.67 million, compared to $2.14 million for the three months ended September 30, 2021. This increase of $1.53 million, or 71%, in the 2022 period was due to increases in our general and administrative expenses of $863,000, in our professional fees of $354,000 and in our payroll and related expenses of $307,000.


The $863,000 increase in our general and administrative expenses was primarily due to the combination of a $384,000 increase in our clinical trial expenses, a $258,000 increase in supplies, primarily for manufacturing Hemopurifiers, a $140,000 increase in subcontract expenses related to our government contracts, a $50,000 increase in our rent expense and a $32,000 increase in our insurance expense.


The $354,000 increase in our professional fees was primarily due to the combination of a $152,000 increase in our contract labor expense associated with product development and analytical services, a $136,000 increase in our legal fees and a $61,000 increase in our investor relations expenses, primarily related to solicitation expenses associated with our 2022 annual meeting of stockholders.


The $307,000 increase in our payroll and related expenses was due to an increase in our stock-based compensation expense of $112,000. Our cash-based compensation expense increased by $195,000 due to our increased headcount.


In September 2022, the Board of Directors of Exosome Sciences, Inc. (ESI) and Aethlon, as the majority stockholder of ESI, approved the dissolution of ESI. As a result of this dissolution, we recorded a non-cash charge of $142,121 as other expense in the three months ended September 30, 2022.


Aethlon did not record any revenue related to our government contract with the NIH in the three months ended September 30, 2022, compared to approximately $132,000 in the three months ended September 30, 2021. As of September 30, 2022, the Company had approximately $574,000 of deferred revenue related to those contracts as a result of not achieving certain milestones in those contracts. The NIH award contract ended on September 15, 2022 and we presented the required final report to the NCI. Once the NCI completes the close out review of the contract, we expect to recognize as revenue the $574,000 currently recorded as deferred revenue on our September 30, 2022 balance sheet.


As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $3.8 million in the three months ended September 30, 2022, from approximately $2.0 million in the three months ended September 30, 2021.


During the six months ended September 30, 2022, the Company raised approximately $8.9 million in net proceeds under our ATM agreement with H.C. Wainwright & Co., pursuant to sales of our common stock.


The unaudited condensed consolidated balance sheet for September 30, 2022, and the unaudited condensed consolidated statements of operations for the three and six months ended September 30, 2022 and 2021 follow at the end of this release.


Conference Call


The Company will hold a conference call today, Monday, Nov.14, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session.


Interested parties can register for the conference by navigating to


Please note that registered participants will receive their dial in number upon registration.


Interested parties without internet access or unable to pre-register may dial in by calling:








All callers should ask for the Aethlon Medical, Inc. conference call.


A replay of the call will be available approximately one hour after the end of the call through December 14, 2022. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 2753791.


About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company developing the Hemopurifier, a therapeutic blood filtration system indicated for cancer and infectious diseases. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.

The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. In two case studies of patients treated under Emergency Use (EU), the Hemopurifier demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus from the circulation of a human patient.

Additional information can be found at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to launch its clinical trials in Australia and expand its trials in India, the Company’s ability to obtain FDA approval of its new GNA supplier in a timely manner, the Company’s ability to submit to the FDA and have the FDA approve an EUA for the MPVX, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, the Company’s ability to raise additional funds, the Company’s ability to obtain Emergency Use authorization from the FDA for use of the Hemopurifier to treat patients with the MPXV; the Company’s ability expand its clinical trials into other areas of cancer, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2022, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.


Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.


Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC







Consolidated Balance Sheets



September 30,



March 31,


CURRENT ASSETS                
Cash   $ 19,604,025     $ 17,072,419  
Accounts receivable     114,849       127,965  
Prepaid expenses     784,638       956,623  
TOTAL CURRENT ASSETS     20,503,512       18,157,007  
Property and equipment, net     1,138,623       441,238  
Right-of-use lease asset     1,282,328       696,698  
Patents, net     1,925       2,200  
Restricted cash     87,506       87,506  
Deposits     33,305       33,305  
TOTAL ASSETS   $ 23,047,199     $ 19,417,954  
Accounts payable   $ 361,001     $ 499,962  
Due to related parties     177,527       155,742  
Deferred revenue     574,245       344,547  
Lease liability, current portion     247,144       126,905  
Other current liabilities     741,529       696,893  
TOTAL CURRENT LIABILITIES     2,101,446       1,824,049  
Lease liability, less current portion     1,077,529       602,505  
TOTAL LIABILITIES     3,178,975       2,426,554  
Common stock, par value of $0.001, 60,000,000 shares authorized; 22,946,232 and 15,419,163 issued and outstanding     22,948       15,421  
Additional-paid in capital     156,887,555       147,446,868  
Accumulated deficit     (137,042,279 )     (130,329,181 )
Noncontrolling interests           (141,708 )
TOTAL STOCKHOLDERS' EQUITY     19,868,224       16,991,400  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY   $ 23,047,199     $ 19,417,954  







Consolidated Statements of Operations
For the three and six month periods ended September 30, 2022 and 2021


    Three Months     Three Months     Six Months     Six Months  
    Ended 9/30/22     Ended 9/30/21     Ended 9/30/22     Ended 9/30/21  
Government contract revenue   $     $ 131,966     $     $ 263,932  
OPERATING COSTS AND EXPENSES                                
Professional fees     1,003,870       649,460       1,847,899       1,232,929  
Payroll and related     1,112,955       805,608       2,142,641       1,822,350  
General and administrative     1,548,484       685,702       2,582,505       1,315,895  
Total operating expenses     3,665,309       2,140,770       6,573,045       4,371,174  
OPERATING LOSS     (3,665,309 )     (2,008,804 )     (6,573,045 )     (4,107,242 )
OTHER EXPENSE                                
Loss on dissolution of subsidiary     142,121             142,121        
NET LOSS   $ (3,807,430 )   $ (2,008,804 )   $ (6,715,166 )   $ (4,107,242 )
Loss attributable to noncontrolling interests           (825 )           (1,960 )
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.   $ (3,807,430 )   $ (2,007,979 )   $ (6,715,166 )   $ (4,105,282 )
Basic and diluted net loss available to common stockholders per share   $ (0.18 )   $ (0.13 )   $ (0.37 )   $ (0.29 )
Weighted average number of common shares outstanding     20,744,999       15,386,486       18,130,177       14,114,639